AMIC accelerator technology looks positive for Mo-99 production

Advanced Medical Isotope Corporation (AMIC) has achieved "encouraging results" from initial tests of its accelerator technology for the domestic production of molybdenum-99 (Mo-99).

AMIC is conducting the tests at Idaho State University in Pocatello, Idaho, in conjunction with researchers from the University of Missouri in Columbia, Mo.

The technology is expected to be able to capture a significant portion of the U.S. domestic market, and will employ low-enriched uranium, according to James C. Katzaroff, CEO of AMIC. He added that the first production facility would most likely be in either Washington or Idaho and would take a much shorter time to build than comparable reactor systems.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.